Humana Inc. (HUM) Given Sector Perform Rating at Royal Bank Of Canada
Royal Bank Of Canada reissued their sector perform rating on shares of Humana Inc. (NYSE:HUM) in a report released on Thursday morning, MarketBeat Ratings reports. The brokerage currently has a $242.00 price target on the insurance provider’s stock, down from their prior price target of $245.00.
HUM has been the subject of a number of other reports. ValuEngine raised shares of Humana from a hold rating to a buy rating in a research report on Friday, September 1st. BidaskClub lowered shares of Humana from a buy rating to a hold rating in a research report on Wednesday, July 19th. Bank of America Corporation increased their price target on shares of Humana from $270.00 to $275.00 and gave the stock a buy rating in a research report on Friday, July 14th. Zacks Investment Research lowered shares of Humana from a strong-buy rating to a hold rating in a research report on Tuesday, October 17th. Finally, Piper Jaffray Companies increased their price target on shares of Humana to $280.00 and gave the stock an overweight rating in a research report on Thursday, August 3rd. Thirteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Humana presently has a consensus rating of Hold and a consensus price target of $252.81.
Humana (HUM) traded down $3.07 during mid-day trading on Thursday, reaching $244.39. 1,265,400 shares of the company’s stock were exchanged, compared to its average volume of 1,376,685. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. Humana has a 52 week low of $186.25 and a 52 week high of $264.56. The stock has a market capitalization of $34,913.58, a price-to-earnings ratio of 20.85, a PEG ratio of 1.68 and a beta of 0.91.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. During the same period in the prior year, the firm earned $3.18 earnings per share. The business’s quarterly revenue was down 3.0% on a year-over-year basis. analysts forecast that Humana will post 11.64 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Humana Inc. (HUM) Given Sector Perform Rating at Royal Bank Of Canada” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/13/humana-inc-hum-given-sector-perform-rating-at-royal-bank-of-canada.html.
The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a $0.40 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.65%. Humana’s dividend payout ratio (DPR) is currently 12.59%.
In other news, VP Timothy S. Huval sold 7,803 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the sale, the vice president now directly owns 8,831 shares in the company, valued at $2,279,634.34. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider William Kevin Fleming sold 3,071 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the completion of the sale, the insider now owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,660 shares of company stock valued at $5,319,600. Company insiders own 0.80% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Mackenzie Financial Corp increased its stake in shares of Humana by 3.6% in the third quarter. Mackenzie Financial Corp now owns 6,642 shares of the insurance provider’s stock valued at $1,618,000 after buying an additional 232 shares in the last quarter. Pinebridge Investments L.P. increased its stake in shares of Humana by 95.2% in the third quarter. Pinebridge Investments L.P. now owns 3,464 shares of the insurance provider’s stock valued at $844,000 after buying an additional 1,689 shares in the last quarter. Tredje AP fonden increased its stake in shares of Humana by 111.8% in the third quarter. Tredje AP fonden now owns 53,004 shares of the insurance provider’s stock valued at $12,935,000 after buying an additional 27,984 shares in the last quarter. Commerzbank Aktiengesellschaft FI acquired a new stake in shares of Humana in the third quarter valued at $322,000. Finally, Skandinaviska Enskilda Banken AB publ increased its stake in shares of Humana by 4.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 25,974 shares of the insurance provider’s stock valued at $6,328,000 after buying an additional 1,000 shares in the last quarter. Institutional investors own 96.15% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.